Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease

Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530 · see citing works

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177 · see citing works

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · see citing works

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,783 · see citing works

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1× · see citing works

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 1,849 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · see citing works

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · see citing works

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · see citing works

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people

Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225 · see citing works

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020 · see citing works

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · see citing works

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · see citing works

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

Packer, M. (2022) · Circulation · doi:10.1161/circulationaha.122.061732 · Cited by 443 · see citing works

10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>

American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438 · see citing works

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386 · see citing works

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010007 · Cited by 313 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

Patel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Claggett, B. L., Fletcher, R. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069568 · Cited by 210 · see citing works

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200 · see citing works

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca‐Fontán, F., Vecchio, L. D., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 184 · see citing works

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 177 · see citing works

The benefits of GLP-1 drugs beyond obesity

Drucker, D. J. (2024) · Science · doi:10.1126/science.adn4128 · Cited by 169 · see citing works

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057934 · Cited by 132 · see citing works

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Staplin, N., Haynes, R., Judge, P., Wanner, C., Green, J., Emberson, J., Preiss, D., Mayne, K., Ng, S., Sammons, E. L., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00321-2 · Cited by 102 · see citing works

Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Mantsiou, C., Karagiannis, T., Kakotrichi, P., Malandris, K., Avgerinos, I., Liakos, A., Tsapas, A., & Bekiari, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14108 · Cited by 98 · see citing works

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

Neves, J. S., Borges‐Canha, M., Vasques‐Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D. M., Leite-Moreira, A. F., Hernandez, A. F., Prato, S. D., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.048 · Cited by 72 · see citing works

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

van Ruiten, C. C., der Beek, A. B. V. D. A., IJzerman, R. G., Nieuwdorp, M., Hoogenberg, K., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14410 · Cited by 54 · see citing works

Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

Botros, F. T., Gerstein, H. C., Malik, R., Nicolay, C., Hoover, A., Turfanda, I., Colhoun, H. M., & Shaw, J. E. (2023) · Diabetes Care · doi:10.2337/dc23-0231 · Cited by 42 · see citing works

2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 312 · see citing works

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120 · see citing works

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108 · see citing works

Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy

Hou, G., Dong, Y., Jiang, Y., Zhao, W., Zhou, L., Cao, S., & Li, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1602594 · Cited by 80 · see citing works

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074545 · Cited by 70 · see citing works

Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets

Mericskay, M., Zuurbier, C. J., Heather, L. C., Karlstaedt, A., Inserte, J., Bertrand, L., Kararigas, G., Ruiz‐Meana, M., Maack, C., & Schiattarella, G. G. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01166-7 · Cited by 66 · see citing works

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 87 · see citing works

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application

Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 72 · see citing works

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works

Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease

Neuen, B. L., Yeung, E. K., Rangaswami, J., & Vaduganathan, M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae258 · Cited by 48 · see citing works

Type 2 Diabetes and the Multifaceted Gut-X Axes

Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 36 · see citing works

Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management

Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 33 · see citing works

Risk-directed management of chronic kidney disease

Blum, M. F., Neuen, B. L., & Grams, M. E. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00931-8 · Cited by 29 · see citing works

Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis

Shokravi, A., Seth, J., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02900-8 · Cited by 30 · see citing works

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 29 · see citing works

Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies

Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 24 · see citing works

Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes

Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 23 · see citing works

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update

Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 27 · see citing works

Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies

Scheen, A. J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101594 · Cited by 20 · see citing works

SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes

Wu, Q., Zhang, J., Zhang, F., & Li, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1601633 · Cited by 20 · see citing works

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1673 · Cited by 20 · see citing works

SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure: A Scientific Statement of the HFA and the HFAI

Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 20 · see citing works

Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis

Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17 · see citing works

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease

Hong, A. T., Lin, F., Luu, I. Y.-K., Shin, L., Han, S. M., Armstrong, D. G., & Tan, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112982 · Cited by 16 · see citing works

A Clinical Review of the Connections Between Diabetes Mellitus, Periodontal Disease, and Cardiovascular Pathologies

Țica, O., Romanul, I. M., Ciavoi, G., Pantea, V. A., Scrobotă, I., Șipoș, L. R., Daina, C. M., & Ţică, O. (2025) · Biomedicines · doi:10.3390/biomedicines13092309 · Cited by 14 · see citing works

Incretins and the cardiovascular system: bridging digestion with metabolism

Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 15 · see citing works

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

He, L., Li, J., Cheng, X., Luo, L., & Huang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1509561 · Cited by 13 · see citing works

SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes

Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 12 · see citing works

Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus

Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 12 · see citing works

Effects of GLP ‐1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta‐analysis

Alammari, N. A., ALSHEHRI, A. S., Khalaf, A. A., Alamri, R., Alhalal, N., Sultan, M. A. A., Ogran, N., Aljohani, R., Alasmari, S. M. S., Alsharif, S. B., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16476 · Cited by 12 · see citing works

Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond

Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 15 · see citing works

Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis

Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 10 · see citing works

A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes

Tuttle, K. R., Kornowske, L. M., Jones, C. R., Reynolds, C. L., Alicic, R. Z., Daratha, K. B., Neumiller, J. J., Duru, O. K., Nicholas, S. B., Norris, K. C., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000857 · Cited by 10 · see citing works

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Yeo, D., Jo, Y., Jeong, J., Jeong, Y. D., Woo, H. G., Son, Y., Kim, S., Rhee, S. Y., & Yon, D. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70298 · Cited by 10 · see citing works

Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data

Fishkin, A., Rozenberg, A., Schechter, M., Sehtman-Shachar, D. R., Aharon‐Hananel, G., Leibowitz, G., Yanuv, I., & Mosenzon, O. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70066 · Cited by 10 · see citing works

Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction

Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112595 · Cited by 9 · see citing works

A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes

Blum, M. F., Mehta, S., Surapaneni, A., Carrero, J. J., Zhang, D. “., Inker, L. A., Horwitz, L. I., Blecker, S., Shin, J., & Grams, M. E. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000902 · Cited by 9 · see citing works

Obesity Medication Treatment Perspectives Among People with Overweight or Obesity

Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8 · see citing works

Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial

Tuttle, K. R., Mann, J. F. E., Mayrdorfer, M., Rayner, B. L., Pugliese, G., Pratley, R. E., Perkovic, V., Mahaffey, K. W., Kashihara, N., Jeppesen, O. K., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000974 · Cited by 8 · see citing works

Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists

Cosentino, N., Trombara, F., Metrio, M. D., Molinari, C., Genovese, S., Pontone, G., & Marenzi, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081202 · Cited by 8 · see citing works

The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms

Mansoor, M. A. (2025) · Physiologia · doi:10.3390/physiologia5030034 · Cited by 7 · see citing works

Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment

Dong, H., Chang, L., Tian, T., Shi, R., Yu, K., Wang, C., Liu, Z., Jin, Q., Wang, J., He, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724965 · Cited by 7 · see citing works

Total-body positron emission tomography: Investigating mechanisms in cardiovascular-kidney-metabolic syndrome

Brown, J. M., & Huck, D. M. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102299 · Cited by 6 · see citing works

Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management

Singh, A., Kesani, H., Verma, S., Saleh, T. M., & Rai, M. (2025) · Cureus · doi:10.7759/cureus.94134 · Cited by 6 · see citing works

Drug-coated balloons and diabetes: a review

Frazzetto, M., Malakouti, S., Khialani, B. V., Gurgoglione, F. L., & Cortese, B. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02922-2 · Cited by 6 · see citing works

Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025

Wilk, M. M., & Tymków, R. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120484 · Cited by 6 · see citing works

Trends in nephrology: from “diabetic kidney disease” to “CKD with risk factor diabetes”

Speeckaert, M. M., & Rossing, P. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf134 · Cited by 5 · see citing works

SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Ahmed, A. A. O., Ahmed, O., Ahmed, R. A. O., Ahmed, R. A. O., Mohammed, M. A. E. A., Ahmed, Y., Abbas, M., Ibrahim, M. A. A., Abakar, M. E. M., Dahab, K. E. M., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05455-4 · Cited by 5 · see citing works

Interventions for the prevention and management of cardiometabolic multiple long-term conditions

Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P. M., Lawson, C. A., Seidu, S., & Khunti, K. K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 5 · see citing works

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 6 · see citing works

The combination of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis

Avogaro, A., Neccia, M., Delfini, M., Franculli, A., Enea, G., Magli, A., Bemporad, J. A., & Fadini, G. P. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02666-9 · Cited by 4 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines

Várkonyi, T. T., Kupai, K., Kang, H. L., Matusovits, D., Priksz, D., Várkonyi, Á., Lengyel, C., & Pósa, A. (2026) · Antioxidants · doi:10.3390/antiox15050553 · Cited by 4 · see citing works

Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus

Gohda, T., Kamei, N., Tanaka, M., Furuhashi, M., Sato, T., Kubota, M., Sanuki, M., Koshida, T., Hagiwara, S., Suzuki, Y., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70011 · Cited by 4 · see citing works

Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome

Zhu, H., Zheng, L., Zhao, K., Wang, X., Ma, Z., Zeng, A., Zhao, W., Zhang, W. Y., Han, L., & Huang, Y. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3340719 · Cited by 4 · see citing works

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Caramori, M. L., REPETTO, E., Perkins, C., Pandey, A., & Rossing, P. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70640 · Cited by 4 · see citing works

Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention

Gerstein, H. C., & Sattar, N. A. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102645 · Cited by 4 · see citing works

Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data

Patel, N., Gaonkar, M. P., Pampana, A., Shetty, N. S., Vekariya, N., Li, P., Arora, G., & Arora, P. K. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.01.003 · Cited by 3 · see citing works

National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017–2024

Car, M., Erceg, D., Udovičić, M., Bokun, T., & Rahelić, D. (2025) · Medicina · doi:10.3390/medicina61122210 · Cited by 3 · see citing works

Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension

Fazio, S., & Affuso, F. (2025) · Biomedicines · doi:10.3390/biomedicines13123102 · Cited by 3 · see citing works

Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease

Economos, H., & MacIsaac, R. J. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.109457 · Cited by 4 · see citing works

GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes

Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3 · see citing works

Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome

Hua, J., Wang, Q., Liu, Y., Luo, S., Shi, A., Yan, Z., Zhang, J., Gu, W., Zhu, L., Zhang, Y., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03173-5 · Cited by 3 · see citing works

Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance

Mohsen, M., Yi, T. W., Faruque, L. I., Ke, C., Cafazzo, J. A., Pham, Q. N., Sridhar, V. S., Levin, A., Abdel-Qadir, H. M., Persson, F., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag163 · Cited by 3 · see citing works

The therapeutic approach to cardiovascular–kidney–metabolic syndrome

Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 3 · see citing works

The future of glucagon-like peptide-1 receptor agonists in cardiovascular–kidney–metabolic diseases considerations from the ERA Diabesity Working Group

Trillini, M., Jenssen, T. G., Martin, W. P., & Morales, E. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf008 · Cited by 3 · see citing works

Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia

Agarwal, R., Nangaku, M., Chen, L., Wang, A. Y.-M., Yanagita, M., Bavanandan, S., Satirapoj, B., Prasad, N., Lim, S. K., Sriwijitkamol, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000909 · Cited by 4 · see citing works

Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach

Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.102390 · Cited by 3 · see citing works

Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound

Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 3 · see citing works

Evaluation and Management of Obesity in Chronic Kidney Disease

Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4 · see citing works

Cardiovascular-Kidney-Metabolic Health

Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4 · see citing works

Uptake of Goal-Directed Therapies in a Multidisciplinary and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Research Letter

Ouimet, J.-P., Mohsen, M., Ni, H., Weisman, A., Udell, J. A., & Cherney, D. Z. I. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251380509 · Cited by 2 · see citing works

Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA

Gryglewska-Wawrzak, K., Kapłon‐Cieślicka, A., Pawlak, A., Tomaszuk−Kazberuk, A., Rubiś, P., Niedziela, J. T., & Bielecka-Dabrowa, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111726 · Cited by 2 · see citing works

Effects of proANP 31–67 in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling

da Silva, G. J. J., Stefani, S., Parvan, R., Frisk, M., Shen, X., Cardinali, M. A., Strand, M. E., Rypdal, K. B., Stokke, M. K., Attramadal, H., et al. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00339.2025 · Cited by 2 · see citing works

Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease

Tuttle, K. R., Bakris, G. L., Baeres, F. M. M., Bang, C. N., Bax, W. A., Belmar, N., Musinga, D., Cherney, D. Z. I., Chernin, G., Lim, S. K., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5125 · Cited by 2 · see citing works

Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review

Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 2 · see citing works

Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial

Lv, R., Peng, L., Xu, Y., Du, X., Liu, H. X., Wu, H., Zhang, Y., Li, Q., Jiao, X., Piao, C., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104045 · Cited by 3 · see citing works

Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Vournas, G., Sarvani, A., Mavridou, M., Tentolouris, A., Doumas, M. N., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03699-w · Cited by 2 · see citing works

GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?

Kosjerina, V., & Rossing, P. R. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.001 · Cited by 2 · see citing works

Recurrent hypoglycemia exposure increases the risk of platelet activation and thrombosis in insulin‐treated diabetic rats

Rehni, A. K., Cho, S., Liu, A., Lo, J., Kim, S. S., Khoury, N., Pérez‐Pinzón, M. A., Jy, W., & Dave, K. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16440 · Cited by 2 · see citing works

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis

Neves, J. S., Vale, C., Leite, A. R., & Ferreira, J. P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16603 · Cited by 2 · see citing works

Advances in Cardiorenal Medicine: The Year 2024 in Review

Kazory, A., & Ronco, C. (2025) · Cardiorenal Medicine · doi:10.1159/000544817 · Cited by 1 · see citing works

Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review

Khan, H. K., Ashfaq, Z., Jamil, H., Yaqoob, H., Anthony, N., Dilawar, R., Ahmad, S. B., Nabi, S., Rania, S. A., Saleem, F., et al. (2025) · Cureus · doi:10.7759/cureus.80932 · Cited by 1 · see citing works

Impact of diabetes on outcomes of patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease undergoing percutaneous coronary intervention

Jakob, P., Varbella, F., Linke, A. H.-P., Schwarz, B., Felix, S. B., Seiffert, M., Kesterke, R., Nordbeck, P., Witzenbichler, B., Lang, I. M., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02745-x · Cited by 1 · see citing works

Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus

An, X., Li, X., Zhang, H., Jia, Q.-Y., Zhang, Y., & Yang, G.-G. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.111280 · Cited by 1 · see citing works

Unravelling Diabetes Endotypes and Associated Pathophysiology for Precision Medicine in Diabetes: Ready for Prime Time?

Ronald, C. W., Lin, H., & Yu, G. (2025) · Diabetes Care · doi:10.2337/dci25-0067 · Cited by 1 · see citing works

Cardiovascular benefits of GLP-1 receptor agonists in nonobese patients with HFpEF

Haider, E., Ahmad, N., Khan, S., & Imran, S. B. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004283 · Cited by 1 · see citing works

Tubular Biomarkers and Retinal Microvasculature

Cohen‐Hagai, K. (2025) · Kidney360 · doi:10.34067/kid.0000001002 · Cited by 1 · see citing works

Long‐Term Mortality and Cardiorenal Outcomes After Metabolic and Bariatric Surgery in Patients With Type 2 Diabetes and Obesity: A Retrospective Cohort Study

Li, Z.-Y., Kao, C., Liu, M., Hung, K., Lai, C., Lin, Y., & Wu, J. (2025) · World Journal of Surgery · doi:10.1002/wjs.70210 · Cited by 1 · see citing works

Prognostic Significance of Noninvasive Simultaneous Renal and Cardiac Perfusion: Interrogating Mechanisms of Cardiovascular-Kidney Interactions

Alabi, O., Lan, Z., Huck, D. M., Kijewski, M. F., Park, M.-A., Hainer, J. M., Carre, S. L., Perillo, A., Martell, L., Barrett, L., et al. (2026) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.125.018979 · Cited by 2 · see citing works

Association Between Off‐Label Use of Cardio‐Kidney‐Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real‐World Evidence Study

Pandey, A., REPETTO, E., Perkins, C., Rossing, P. R., & Caramori, M. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70597 · Cited by 1 · see citing works

Economic burden of type 2 diabetes management in France according to clinical characteristics

Guerci, B., Blanc-Bisson, C., Vicaut, É., de Pouvourville, G., Detournay, B., Emery, C., Bureau, I., Ihaddadene‐Salzgeber, T., Levrat‐Guillen, F., & Riveline, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70586 · Cited by 1 · see citing works

Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation

Wang, C.-H., Chang, W.-C., Chen, H.-Y., Chen, P., Lin, M. H., & Lee, C.-H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02151-x · Cited by 1 · see citing works

The Epidemiology, Prevention, and Control of Type 2 Diabetes in Low- and Middle-Income Countries

Kocher, E. L., Teufel, F., Carrillo-Larco, R. M., Chakkalakal, R. J., & Ali, M. K. (2026) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-081624-060046 · Cited by 1 · see citing works

Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists

Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1 · see citing works

Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease

Node, K., Batterham, R. L., Liu‐Seifert, H., Li, R., Yoshino, M., Oura, T., Tanizawa, Y., & Komuro, I. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2686052 · Cited by 1 · see citing works

Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes

Neumiller, J. J., Deng, Y., SWARNA, K. S., Polley, E. C., Herrin, J. S., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Mickelson, M. M., Dryden, K., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.007 · Cited by 1 · see citing works

Comparative cardiovascular outcomes of GLP-1 receptor agonists vs. SGLT2 inhibitors in type 2 diabetes: a large-scale real-world cohort analysis

Ukita, K., Nowak, L., Schmelter, F., Sina, C., & Tilz, R. R. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02970-y · Cited by 1 · see citing works

A Framework for Risk-Based Implementation of Combination Therapy in CKD

Yeung, E. K., Rangaswami, J., Tuttle, K. R., Grams, M. E., Tangri, N., Vaduganathan, M., & Neuen, B. L. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001158 · Cited by 1 · see citing works

Efficacy and Safety of GLP ‐1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

Kaur, R., & Singh, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71031 · Cited by 1 · see citing works

Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use

Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 1 · see citing works

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 177 · see citing works

Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis

Chuang, M., Ho, C.-W., Wang, H., Pan, H., Wu, V., Tu, Y., & Chen, J. (2026) · Canadian Medical Association Journal · doi:10.1503/cmaj.250369

Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 4 · see citing works

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

Neves, J. S., Borges‐Canha, M., Vasques‐Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D. M., Leite-Moreira, A. F., Hernandez, A. F., Prato, S. D., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.048 · Cited by 72 · see citing works

Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes

Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 38 · see citing works